Antifungal resistance in Candida spp within the intra-abdominal cavity : study of resistance acquisition in patients with serial isolates
Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: Antifungal susceptibility testing is mostly conducted on blood-cultured Candida spp isolates. Because the intra-abdominal cavity has been highlighted as a hidden echinocandin-resistant C. glabrata reservoir, we assessed whether testing sequential isolates from a given patient might increase the chances of detecting antifungal resistance.
METHODS: Intra-abdominal initial and sequential isolates from the same species from patients included in the CANDIdaemia in MADrid study (January 2019 to June 2022) were studied. We assessed antifungal susceptibility to amphotericin B, azoles, anidulafungin, micafungin, and ibrexafungerp using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology and molecularly characterized resistant isolates.
RESULTS: We collected 308 isolates (C. albicans [n = 179/308; 58.1%], C. glabrata [n = 101/308; 32.8%], C. tropicalis [n = 17/308; 5.5%], and C. parapsilosis [n = 11/308; 3.6%]) from 112 patients distributed as incident (n = 125/308) and sequential (n = 183/308). Per patient resistance rates of fluconazole (13.4% [15/112] vs. 8% [9/112]); 5.4% proportions difference (95% CI, -2.7% to 13.5%, p 0.09) and echinocandins (8.9% [10/112] vs. 1.8% [2/112]); 7.1% proportions difference (95% CI; 1.2-12.9%; p 0.01) were higher when considering all available isolates than only incident isolates. Resistance was detected in 18 of 112 patients and would have been overlooked in 11 of 18 (61.1%) patients if only incident isolates had been studied. Of the patients who harboured fluconazole or echinocandin-resistant isolates, 14 of 15 and 8 of 10 had received or were receiving fluconazole or echinocandins, respectively.
DISCUSSION: Testing sequential Candida isolates from intra-abdominal samples is required to detect antifungal resistance, particularly to echinocandins, in patients whose incident isolates turned out to be susceptible. Furthermore, patients with echinocandin-resistant infections had frequently used echinocandins and had common secondary resistance acquisition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 29(2023), 12 vom: 26. Dez., Seite 1604.e1-1604.e6 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2023.08.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361383401 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361383401 | ||
| 003 | DE-627 | ||
| 005 | 20231226085025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2023.08.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361383401 | ||
| 035 | |a (NLM)37640239 | ||
| 035 | |a (PII)S1198-743X(23)00404-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Díaz-García, Judith |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antifungal resistance in Candida spp within the intra-abdominal cavity |b study of resistance acquisition in patients with serial isolates |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: Antifungal susceptibility testing is mostly conducted on blood-cultured Candida spp isolates. Because the intra-abdominal cavity has been highlighted as a hidden echinocandin-resistant C. glabrata reservoir, we assessed whether testing sequential isolates from a given patient might increase the chances of detecting antifungal resistance | ||
| 520 | |a METHODS: Intra-abdominal initial and sequential isolates from the same species from patients included in the CANDIdaemia in MADrid study (January 2019 to June 2022) were studied. We assessed antifungal susceptibility to amphotericin B, azoles, anidulafungin, micafungin, and ibrexafungerp using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology and molecularly characterized resistant isolates | ||
| 520 | |a RESULTS: We collected 308 isolates (C. albicans [n = 179/308; 58.1%], C. glabrata [n = 101/308; 32.8%], C. tropicalis [n = 17/308; 5.5%], and C. parapsilosis [n = 11/308; 3.6%]) from 112 patients distributed as incident (n = 125/308) and sequential (n = 183/308). Per patient resistance rates of fluconazole (13.4% [15/112] vs. 8% [9/112]); 5.4% proportions difference (95% CI, -2.7% to 13.5%, p 0.09) and echinocandins (8.9% [10/112] vs. 1.8% [2/112]); 7.1% proportions difference (95% CI; 1.2-12.9%; p 0.01) were higher when considering all available isolates than only incident isolates. Resistance was detected in 18 of 112 patients and would have been overlooked in 11 of 18 (61.1%) patients if only incident isolates had been studied. Of the patients who harboured fluconazole or echinocandin-resistant isolates, 14 of 15 and 8 of 10 had received or were receiving fluconazole or echinocandins, respectively | ||
| 520 | |a DISCUSSION: Testing sequential Candida isolates from intra-abdominal samples is required to detect antifungal resistance, particularly to echinocandins, in patients whose incident isolates turned out to be susceptible. Furthermore, patients with echinocandin-resistant infections had frequently used echinocandins and had common secondary resistance acquisition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abdominal samples | |
| 650 | 4 | |a Candida | |
| 650 | 4 | |a EUCAST | |
| 650 | 4 | |a Echinocandins | |
| 650 | 4 | |a Fluconazole | |
| 650 | 4 | |a Resistance | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 700 | 1 | |a Machado, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalá, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Reigadas, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Carrillo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Ayala, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-García de la Pedrosa, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a González-Romo, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Cuétara, María Soledad |e verfasserin |4 aut | |
| 700 | 1 | |a García-Esteban, Coral |e verfasserin |4 aut | |
| 700 | 1 | |a Quiles-Melero, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Zurita, Nelly Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Algarra, María |e verfasserin |4 aut | |
| 700 | 1 | |a Durán-Valle, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Quintero, Gabriela Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-García, Aída |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Escribano, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Guinea, Jesús |e verfasserin |4 aut | |
| 700 | 0 | |a CANDIMAD study group |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-García, Judith |e investigator |4 oth | |
| 700 | 1 | |a Mesquida, Aina |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Ana |e investigator |4 oth | |
| 700 | 1 | |a Machado, Marina |e investigator |4 oth | |
| 700 | 1 | |a Alcalá, Luis |e investigator |4 oth | |
| 700 | 1 | |a Reigadas, Elena |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Carrillo, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Escribano, Pilar |e investigator |4 oth | |
| 700 | 1 | |a Guinea, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Ayala, Ana |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Rosaura Pérez |e investigator |4 oth | |
| 700 | 1 | |a González, María Del Carmen Vera |e investigator |4 oth | |
| 700 | 1 | |a Gómez-García De La Pedrosa, Elia |e investigator |4 oth | |
| 700 | 1 | |a Romo, Fernando González |e investigator |4 oth | |
| 700 | 1 | |a Merino-Amador, Paloma |e investigator |4 oth | |
| 700 | 1 | |a Cuétara, María Soledad |e investigator |4 oth | |
| 700 | 1 | |a Muñoz Clemente, Oscar Manuel |e investigator |4 oth | |
| 700 | 1 | |a Berenguer, Víctor Antón |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-García, Aída |e investigator |4 oth | |
| 700 | 1 | |a García-Esteban, Coral |e investigator |4 oth | |
| 700 | 1 | |a Lobato, Oscar Cuevas |e investigator |4 oth | |
| 700 | 1 | |a Bernal, Guadalupe |e investigator |4 oth | |
| 700 | 1 | |a Zurita, Nelly |e investigator |4 oth | |
| 700 | 1 | |a Cobos, Ainhoa Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Muñoz-Algarra, María |e investigator |4 oth | |
| 700 | 1 | |a Romero, Isabel Sánchez |e investigator |4 oth | |
| 700 | 1 | |a Quiles-Melero, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a San Juan Delgado, Florinda |e investigator |4 oth | |
| 700 | 1 | |a Durán-Valle, María Teresa |e investigator |4 oth | |
| 700 | 1 | |a Romero, Yolanda Gil |e investigator |4 oth | |
| 700 | 1 | |a Fraile Torres, Arturo Manuel |e investigator |4 oth | |
| 700 | 1 | |a Martínez-Quintero, Gabriela Andrea |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 29(2023), 12 vom: 26. Dez., Seite 1604.e1-1604.e6 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:12 |g day:26 |g month:12 |g pages:1604.e1-1604.e6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2023.08.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 12 |b 26 |c 12 |h 1604.e1-1604.e6 | ||